Harald Reinhart - 07 Sep 2021 Form 4 Insider Report for Zai Lab Ltd (ZLAB)

Role
Chief Medical Officer
Signature
/s/ Bruce A. Blefeld
Issuer symbol
ZLAB
Transactions as of
07 Sep 2021
Net transactions value
-$1,479,259
Form type
4
Filing time
08 Sep 2021, 21:02:13 UTC
Previous filing
25 Aug 2021
Next filing
10 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZLAB Ordinary Shares Options Exercise $30,000 +10,000 $3.00* 10,000 07 Sep 2021 Direct F1
transaction ZLAB Ordinary Shares Sale $14,300 -100 -1% $143.00* 9,900 07 Sep 2021 Direct F1
transaction ZLAB Ordinary Shares Sale $29,396 -200 -2% $146.98* 9,700 07 Sep 2021 Direct F1, F2
transaction ZLAB Ordinary Shares Sale $44,607 -300 -3.1% $148.69* 9,400 07 Sep 2021 Direct F1, F3
transaction ZLAB Ordinary Shares Sale $300,820 -2,000 -21% $150.41* 7,400 07 Sep 2021 Direct F1, F4
transaction ZLAB Ordinary Shares Sale $998,448 -6,600 -89% $151.28* 800 07 Sep 2021 Direct F1, F5
transaction ZLAB Ordinary Shares Sale $121,688 -800 -100% $152.11* 0 07 Sep 2021 Direct F1, F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZLAB Stock Options (Right to Buy) Options Exercise $0 -10,000 -30% $0.000000 23,334 07 Sep 2021 Ordinary Shares 10,000 $3.00 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a sales plan adopted by the Reporting Person, dated June 2, 2021, expires December 31, 2021 and is intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
F2 Reflects a weighted average sale price of $146.98 per share, at prices ranging from $146.66 to $147.30 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F3 Reflects a weighted average sale price of $148.69 per share, at prices ranging from $148.23 to $148.92 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F4 Reflects a weighted average sale price of $150.41 per share, at prices ranging from $149.80 to $150.78 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F5 Reflects a weighted average sale price of $151.28 per share, at prices ranging from $150.84 to $151.82 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F6 Reflects a weighted average sale price of $152.11 per share, at prices ranging from $151.85 to $152.50 per share. The Reporting Person will provide, upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F7 The options vest in equal annual installments over four years beginning on 5/12/2018, the first anniversary of the date of grant.